Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 8/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.47 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | HBB | P68871 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLA1 | P09884 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23897774 | 0.98 | P2RY6 (0.48) | P2RY6P2RY2P2RY14NT5EP2RY4 | |
| SCHEMBL23898226 | 0.91 | P2RY6 (0.45) | P2RY6P2RY2P2RY14NT5EP2RY4 | |
| SCHEMBL23897725 | 0.91 | P2RY2 (0.45) | P2RY6P2RY2P2RY14NT5EP2RY4 | |
| SCHEMBL21345973 | 0.90 | P2RY6 (0.52) | P2RY6P2RY14NT5ETSHRLMNA | |
| SCHEMBL15828227 | 0.90 | P2RY6 (0.49) | P2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL15828306 | 0.90 | P2RY6 (0.49) | P2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL23898150 | 0.90 | POLB (0.49) | P2RY6P2RY2P2RY4POLA1 | |
| SCHEMBL23897801 | 0.90 | P2RY6 (0.47) | P2RY6P2RY2P2RY14P2RY4POLA1 | |
| SCHEMBL23897496 | 0.89 | DNPH1 (0.52) | P2RY6P2RY2P2RY14P2RY4POLA1 | |
| SCHEMBL23898281 | 0.89 | P2RY6 (0.42) | P2RY6P2RY2P2RY14NT5EP2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210308168-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210308168-A1 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | PNP, PRPF4, HPRT1 | P2RY6 901/4885P2RY2 1011/4885P2RY14 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.